Insider Selling: Applied Therapeutics, Inc. (NASDAQ:APLT) Insider Sells 22,950 Shares of Stock

Applied Therapeutics, Inc. (NASDAQ:APLT) insider Leslie D. Funtleyder sold 22,950 shares of the firm’s stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $0.61, for a total transaction of $13,999.50. Following the transaction, the insider now directly owns 404,961 shares in the company, valued at approximately $247,026.21. This represents a 5.36 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Applied Therapeutics Stock Performance

Shares of Applied Therapeutics stock traded up $0.00 during midday trading on Friday, hitting $0.61. 1,845,842 shares of the company traded hands, compared to its average volume of 5,416,228. The firm’s fifty day moving average price is $0.90 and its 200-day moving average price is $5.14. The stock has a market cap of $70.99 million, a price-to-earnings ratio of -0.38 and a beta of 1.88. Applied Therapeutics, Inc. has a 12 month low of $0.54 and a 12 month high of $10.62.

Analysts Set New Price Targets

Several research analysts have recently commented on APLT shares. UBS Group reaffirmed a “neutral” rating and set a $2.00 target price (down from $13.00) on shares of Applied Therapeutics in a report on Monday, December 2nd. Robert W. Baird cut their target price on Applied Therapeutics from $14.00 to $5.00 and set an “outperform” rating for the company in a research report on Friday, November 29th. Citigroup cut their price objective on shares of Applied Therapeutics from $13.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 29th. William Blair lowered shares of Applied Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, December 23rd. Finally, Royal Bank of Canada reduced their price target on shares of Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating on the stock in a research report on Friday, December 20th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $6.10.

Institutional Trading of Applied Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of APLT. SG Americas Securities LLC boosted its position in shares of Applied Therapeutics by 169.0% during the 4th quarter. SG Americas Securities LLC now owns 40,747 shares of the company’s stock valued at $35,000 after purchasing an additional 25,601 shares in the last quarter. Private Advisor Group LLC bought a new stake in shares of Applied Therapeutics in the 4th quarter worth $35,000. Algert Global LLC bought a new position in shares of Applied Therapeutics during the 2nd quarter worth approximately $110,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Applied Therapeutics during the 3rd quarter valued at $149,000. Finally, Intech Investment Management LLC purchased a new stake in Applied Therapeutics during the third quarter worth about $162,000. Institutional investors own 98.31% of the company’s stock.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.